Table 3.
Coenzyme Q10 and muscle-related diseases.
| Study Design |
Daily Doses | Effects on Symptoms | Effects on Lab or Instrumental Parameters |
Effects on Hard Outcomes | |
|---|---|---|---|---|---|
| Fatigue | RCTs | 200 mg/day, in association with NADH (20 mg/day) | ↓ FIS total score (CFS) | ↑ NAD+/NADH ratio and CoQ10, ATP, citrate synthase levels | Not investigated |
| RCTs | 300–400 mg | ↓ FIS total score | - | Not investigated | |
| Fibromyalgia | RCTs | 100–400 mg | ↓ fatigue (FIQ, VAS) | - | Not investigated |
| Statin-associated myopathy | Meta-analysis of RCTs | ≥200 mg | ↓ fatigue (VAS) | - | Not investigated |
| Other fatigue-related diseases | RCTs | 60–500 mg | ↓ fatigue (FSS) only in multiple sclerosis and in patients awaiting cardiac transplantation with end-stage heart failure | - | Not investigated |
FIQ = Fibromyalgia Impact Questionnaire, FSS = Fatigue Severity Scale, RCTs = randomized clinical trials, VAS = Visual Analog Scale. ↓= it is indicative of a reduction of a marker or a symptom. ↑ = it is indicative of an increase of a marker or a symptom.